Doctors who produced a mixture of patients’ stem cells and an antibiotic as part an alternative treatment for orthopedic conditions like arthritis violated federal laws regulating the making of drugs and biological products, the U.S. Court of Appeals for the District of Columbia Circuit has ruled.
Judge Thomas B. Griffith, writing for the panel, upheld a permanent injunction barring the defendants, including the company Regenerative Sciences, from continuing the practice of making the medical therapy marketed as the “Cultured Regenexx Procedure” at a clinic in Colorado.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
